Rein Therapeutics, Inc. SEC Filings

Rein Therapeutics, Inc. (RNTX) reported insider buying by a 10% owner group. On 11/14/2025, entities affiliated with Voss Capital reported purchasing 104,183 shares of Rein Therapeutics common stock at a weighted average price of $1.2247 per share, with individual trades ranging from $1.1800 to $1.2500. Following this transaction, Voss Value Master Fund, LP is shown as beneficially owning 926,441 shares indirectly, and Voss Value-Oriented Special Situations Fund, LP is shown as beneficially owning 500,000 shares indirectly. The reporting persons state that, as a group, they beneficially own over 10% of Rein Therapeutics’ outstanding common stock and each disclaims beneficial ownership beyond its pecuniary interest.

Rein Therapeutics (RNTX) filed its Q3 2025 report, highlighting clinical and financing updates alongside continued losses. The FDA lifted the full clinical hold on the Phase 2 RENEW trial of LTI-03 for idiopathic pulmonary fibrosis on October 29, 2025, allowing U.S. enrollment to proceed. The study targets up to 120 patients with initial topline data expected in Q3 2026. The company also received authorization to initiate sites in Germany and Poland and previously had MHRA clearance in the U.K.

Financially, Rein reported a Q3 net loss of $5.581M and a nine‑month net loss of $17.904M. Cash and cash equivalents were $4.048M as of September 30, 2025. Management states there is substantial doubt about the company’s ability to continue as a going concern, estimating runway into December 2025. During 2025, it raised modest funds via warrant exercises and exchanges ($1.679M and $3.101M) and a private placement ($0.5M), established an ATM with limited sales, and received three $1.0M Pre‑Paid Advances from Yorkville (net $0.95M each).

As of November 10, 2025, 26,286,382 common shares were outstanding.

Rein Therapeutics announced FDA clearance to resume its U.S. Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis. The company disclosed the update via a press release furnished as Exhibit 99.1 to this report. No financial terms or operational details were provided in this excerpt.

Rein Therapeutics (RNTX): Voss Capital–affiliated entities reported open‑market purchases of common stock. On 10/24/2025, Voss Value Master Fund, L.P. bought 30,176 shares at $1.3904, bringing its beneficially owned balance to 729,616 shares. On 10/27/2025, the fund bought 92,642 shares at $1.37, for a new total of 822,258 shares.

Voss Value‑Oriented Special Situations Fund, L.P. bought 4,840 shares at $1.3687 on 10/27/2025, increasing to 321,608 shares, and 178,392 shares at $1.39 on 10/28/2025, increasing to 500,000 shares. The holdings are reported as indirect through the respective funds. The reporting persons state they are members of a group that collectively beneficially owns over 10% of the outstanding common stock.

Rein Therapeutics (RNTX) entered a third Pre-Paid Advance with Yorkville. On October 23, 2025, the company drew a $1.0 million Pre-Paid Advance, receiving net proceeds of $0.95 million. Under the existing agreement, advances are purchased at 95% of face value, accrue interest at 8% annually (rising to 18% upon certain defaults), and mature 12 months after issuance.

The PPA permits Yorkville to require the company to issue common stock to offset outstanding balances. Earlier tranches included a $1.0 million First Advance on July 29, 2025 and a $1.0 million Second Advance on September 8, 2025, each providing $0.95 million in net proceeds. As of this report, the company issued 953,765 shares at an average price of approximately $1.0562 to offset $1,007,342 under the First Advance, and 927,107 shares at an average price of approximately $1.0825 to offset $1,003,573 under the Second Advance. The third advance was completed as a private placement relying on Section 4(a)(2).

Rein Therapeutics, Inc. furnished a current report on Form 8-K noting that the company issued a press release dated October 9, 2025. The filing indicates the press release was provided as an interactive data file within the Inline XBRL document and is signed by Brian Windsor, Ph.D., Chief Executive Officer.

No financial results, transactions, corporate developments, or other substantive disclosures are included in the text provided here; the filing appears limited to furnishing the press release.

Voss-affiliated investors reported initial beneficial ownership in Rein Therapeutics, Inc. (RNTX). The Form 3, covering an event dated 09/24/2025 and filed on 10/03/2025, shows the filing group collectively beneficially owns over 10% of Rein Therapeutics common stock. The filing lists Voss Value Master Fund, LP with 699,440 shares and Voss Value-Oriented Special Situations Fund, LP with 316,768 shares, held indirectly through Voss Advisors GP, LLC, Voss Capital, LP and Travis W. Cocke. The report is a joint Form 3 by multiple Voss entities and Mr. Cocke and disclaims ownership beyond pecuniary interest.

Rein Therapeutics, Inc. receives a Schedule 13G/A disclosing that several Voss-related entities and Travis W. Cocke hold meaningful stakes in the company. The filing reports specific beneficial ownership amounts: Voss Value Master Fund holds 699,440 shares (3.0%), Voss Value-Oriented Special Situations Fund holds 316,768 shares (1.3%), Voss Advisors GP is attributable to 1,016,208 shares (4.3%), and Voss Capital and Travis W. Cocke are each reported as beneficial owners of 2,666,532 shares (11.3%). Those percentages are calculated against 23,547,429 shares outstanding as disclosed in the issuer’s registration statement. The cover pages show sole voting and dispositive power for the reported amounts and the filing includes a certification that the shares were not acquired to change or influence control of the issuer.

Rein Therapeutics (RNTX) reports that the RENEW Phase 2 clinical trial is subject to a clinical hold, creating uncertainty about timing and the studies or actions needed to resolve the hold. The company warns that delays could strain its cash resources and affect its ability to fund the trial and operations through completion. It also notes the risk that early-stage results may not be replicated later, potential difficulties enrolling patients, and challenges integrating Qureight's deep-learning platform into the trial. The filing points readers to the company’s 2024 Form 10-K for additional risk factors and reiterates standard forward-looking statement disclaimers.